Search results
Results from the WOW.Com Content Network
Dexlansoprazole is used to heal and maintain healing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). [2] It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. [8]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan. Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925. [12] One of the firm's mainstay drugs is Actos (pioglitazone), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It ...
Takeda's treatment will be available in stick packs of 2 milligram doses by the end of February, the company said. The company has set wholesale acquisition cost for the therapy, given twice daily ...
Lansoprazole is used for treatment of: [3] Ulcers of the stomach and duodenum, and NSAID-induced ulcers; Helicobacter pylori infection, alongside antibiotics (adjunctive treatment), treatment to kill H. pylori causing ulcers or other problems involves using two other drugs besides lansoprazole known as "triple therapy", and involves taking twice daily for 10 or 14 days lansoprazole ...
Expanded access or compassionate use is the use of an unapproved drug or medical device under special forms of investigational new drug applications (IND) or IDE application for devices, outside of a clinical trial, by people with serious or life-threatening conditions who do not meet the enrollment criteria for the clinical trial in progress.
Brentuximab vedotin [6] consists of the chimeric monoclonal antibody brentuximab (cAC10, which targets the cell-membrane protein CD30) linked with maleimide attachment groups, cathepsin-cleavable linkers (valine-citrulline), and para-aminobenzylcarbamate spacers to three to five units of the antimitotic agent monomethyl auristatin E (MMAE, reflected by the 'vedotin' in the drug's name). [7]
Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, [2] under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus. [3]